Investors & Media


March 21, 2022

NGM Bio to Host the First of Four Virtual R&D Events on March 30, 2022

March 8, 2022

NGM Bio Announces Oral and Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio at Upcoming 2022 AACR Annual Meeting

March 1, 2022

NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results

February 28, 2022

NGM Bio to Participate in the Cowen 42nd Annual Health Care Conference

February 7, 2022

NGM Bio’s NGM621 Receives Fast Track Designation from the FDA for the Treatment of Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration

January 20, 2022

NGM Bio to Participate in Upcoming Investor Conferences

January 10, 2022

NGM Bio Outlines 2022 Strategic Priorities Across Its Portfolio of Clinical-Stage Oncology, Retinal and Liver and Metabolic Programs

January 6, 2022

NGM Bio to Present at 40th Annual J.P. Morgan Healthcare Conference

Displaying 11 - 18 of 18

Contact Information

investor relations

media relations